Company Long-Term Loans and Borrowings: Cidara (CDTX)

The price visualization on GURU.Markets for Cidara Therapeutics (CDTX) shows long-term debt amounting to 0.00. Cidara Therapeutics is reducing drug development costs through partnerships with external research centers. The business relies on exclusive patents in the field of infection prevention for high-risk groups. This results in the creation of a closed-loop immunotherapy cycle that prevents patients from switching to alternative treatment methods.

This metric captures the total volume of credit obligations with maturities exceeding one year, allowing for an assessment of long-term financial stability and the leverage level of the capital structure. Analyzing long-term debt is critically important for Cidara Therapeutics (CDTX), as high capital burn and the risks of clinical failures mean that excessive debt could accelerate the loss of solvency for the biotech startup.